Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visterra-Serum Combine Forces For Dengue Therapy

This article was originally published in Scrip

Executive Summary

US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.

You may also be interested in...



Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel